These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

960 related articles for article (PubMed ID: 8450043)

  • 1. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
    Hodsman AB; Fraher LJ
    Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?
    Delmas PD; Vergnaud P; Arlot ME; Pastoureau P; Meunier PJ; Nilssen MH
    Bone; 1995 Jun; 16(6):603-10. PubMed ID: 7669436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
    Cosman F; Nieves J; Shen V; Lindsay R
    J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
    Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
    J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An acute intake of phosphate increases parathyroid hormone secretion and inhibits bone formation in young women.
    Kärkkäinen M; Lamberg-Allardt C
    J Bone Miner Res; 1996 Dec; 11(12):1905-12. PubMed ID: 8970892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
    Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical markers of bone metabolism in infants and children under intravenous corticosteroid therapy.
    Siomou E; Challa A; Tzoufi M; Papadopoulou ZL; Lapatsanis PD; Siamopoulou A
    Calcif Tissue Int; 2003 Oct; 73(4):319-25. PubMed ID: 12874699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
    Kuntz D; Marie P; Berhel M; Caulin F
    Int J Clin Pharmacol Res; 1986; 6(2):157-62. PubMed ID: 3522444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical markers of bone turnover for the clinical assessment of bone metabolism.
    Taylor AK; Lueken SA; Libanati C; Baylink DJ
    Rheum Dis Clin North Am; 1994 Aug; 20(3):589-607. PubMed ID: 7984780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study of bone-related biochemical changes at the menopause.
    Nordin BE; WIshart JM; Clifton PM; McArthur R; Scopacasa F; Need AG; Morris HA; O'Loughlin PD; Horowitz M
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):123-30. PubMed ID: 15212654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study.
    Szulc P; Munoz F; Marchand F; Chapuy MC; Delmas PD
    Calcif Tissue Int; 2003 Dec; 73(6):520-30. PubMed ID: 12958693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
    Uretmen S; Gol M; Cimrin D; Irmak E
    Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
    Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
    Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone may maintain bone formation in hibernating black bears (Ursus americanus) to prevent disuse osteoporosis.
    Donahue SW; Galley SA; Vaughan MR; Patterson-Buckendahl P; Demers LM; Vance JL; McGee ME
    J Exp Biol; 2006 May; 209(Pt 9):1630-8. PubMed ID: 16621944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis.
    Pietschmann P; Resch H; Krexner E; Woloszczuk W; Willvonseder R
    Acta Med Austriaca; 1991; 18(5):114-6. PubMed ID: 1796722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.